(R)-(+)-N,N-dimethyl-α-(2-naphthyl)ethylamine | 64822-34-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (R)-(+)-N,N-dimethyl-α-(2-naphthyl)ethylamine
• 英文别名: R(+)-N,N-dimethyl-α-(2-naphthyl)ethylamine；(+)(R)-N,N-Dimethyl-1-(2-naphthyl)-ethylamin；N,N-Dimethyl-α(2-naphthyl)-aethylamin；(1R)-N,N-dimethyl-1-naphthalen-2-ylethanamine
• CAS: 64822-34-0
• 化学式: C₁₄H₁₇N
• 分子量: 199.296
• InChiKey: QGUBXRUCYKDNFB-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (R)-(+)-N,N-dimethyl-α-(2-naphthyl)ethylamine 生成 N,N-dimethyl-1-(naphthalen-2-yl-3-d)ethan-1-amine
  参考文献：
  名称：

  Chiral metal complexes. 4. Resolution of racemic tertiary phosphines with chiral palladium(II) complexes. The chemistry of diastereomeric phosphine palladium(II) species in solution

  摘要：

  DOI：

  10.1021/ja00466a020
• 作为产物：
  描述：

  聚合甲醛 、 (R)-(-)-α-(2-naphthyl)ethylammonium (R,R) hydrogen tartrate 在 甲酸 作用下， 以 水 为溶剂， 反应 15.0h， 以99%的产率得到(R)-(+)-N,N-dimethyl-α-(2-naphthyl)ethylamine
  参考文献：
  名称：

  手性卤代[N,N-二甲基-α-(2-萘基)乙胺-3,C,N]汞(II)配合物的合成与结构

  摘要：

  摘要 HgCl2 与对映体纯的 3-锂硫基-(S)-(-) 或 (R)-(+)-N,N-二甲基-α-(2-萘基)乙胺、(S) 或 (R)-LiTMNA 反应, 生产 (S)c(R)Hg-{HgCl[C10H6CH(Me)NMe2]}, 2a', 或 (S)c(R)Hg-{HgCl[C10H6CH(Me)NMe2]}, 2a, in公平的收益。溴化物 (2b) 和碘化物 (2c) 类似物分别通过 2a 与 NaBr 和 NaI 反应以良好的产率制备。2a'、2b 和2c 的晶体结构表明，每种化合物中的Hg 原子在固态时呈三配位、T 形、略呈锥形。这三种化合物仅形成 (S)c(R)Hg 或 (R)c(S)Hg 非对映异构体，平均 Hg-C 和 Hg-N 距离分别为 2.08 (2) A 和 2.65 (2) A。

  DOI：

  10.1016/s0022-2860(98)00509-2

文献信息

• Horner, L.; Simons, G., Phosphorus and Sulfur and the Related Elements, 1983, vol. 15, p. 165 - 176
  作者：Horner, L.、Simons, G.

  DOI：——

  日期：——
• Dunina, V. V.; Zalevskaya, O. A.; Smolyakova, I. P., Journal of general chemistry of the USSR, 1986, vol. 56, p. 599 - 607
  作者：Dunina, V. V.、Zalevskaya, O. A.、Smolyakova, I. P.、Potapov, V. M.

  DOI：——

  日期：——
• HORNER, L.;SIMONS, G., PHOSPH. AND SULFUR, 1983, 15, N 2, 165-175
  作者：HORNER, L.、SIMONS, G.

  DOI：——

  日期：——
• BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS
  申请人：Bradner James Elliot

  公开号：US20130018103A1

  公开（公告）日：2013-01-17

  In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel bifunctional, trifunctional, or multifunctional compounds for inhibiting histone deacetylases, and pharmaceutically acceptable salts and derivatives thereof. The present invention further provides methods for treating disorders regulated by histone deacetylase activity (e.g., proliferative diseases, cancer, inflammatory diseases, protozoal infections, hair loss, etc.) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. The present invention also provides methods for preparing compounds of the invention.
• HISTONE DEACETYLASE INHIBITORS
  申请人：President & Fellows of Harvard College

  公开号：US20160143874A1

  公开（公告）日：2016-05-26

  In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for exmaple. The present invention also provides methods for preparing compounds of the invention and intermediates thereto.